Search Results - "Vernillet, L."

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma by RAYMOND, E, FABBRO, M, VERMILLET, L, ARMAND, J. P, BOIGE, V, RIXE, O, FRENAY, M, VASSAL, G, FAIVRE, S, SICARD, E, GERMA, C, RODIER, J. M

“…To assess the antitumour activity and safety profile of irinotecan and its pharmacokinetic interactions with anticonvulsants in patients with glioblastoma…”
Get full text

Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors by GELMON, Karen A, LATREILLE, Jean, BESENVAL, Michele, EISENHAUER, Elizabeth, TOLCHER, Anthony, GENIER, Luc, FISHER, Bryn, FORAND, Dominique, D'ALOISIO, Susan, VERNILLET, Laurent, DAIGNEAULT, Luc, LEBECQ, Ann

“…To define the maximum-tolerated dose, recommended phase II dose (RD), dose-limiting toxicity (DLT), and pharmacokinetics of a novel taxane, RPR 109881A,…”
Get full text

Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects by Khosravan, R., Grabowski, B., Wu, J. T., Joseph‐Ridge, N., Vernillet, L.

“…Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients with gout…”
Get full text

Effects of age and gender on febuxostat pharmacokinetics, pharmacodynamics, and safety in healthy subjects by Khosravan, R., Kukulka, M., Wu, J. T., Joseph‐Ridge, N., Vernillet, L.

“…Background Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients…”
Get full text

Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects by Khosravan, R., Erdman, K., Vernillet, L., Wu, J. T., Joseph‐Ridge, N., Umeda, S., Mulford, D.

“…Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients with gout…”
Get full text

Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study by Lortholary, A, Maillard, P, Delva, R, Boisdron-Celle, M, Perard, D, Vernillet, L, Besenval, M, Gamelin, E

“…This phase I study evaluated the maximum tolerated dose, dose-limiting toxicity and recommended dose of docetaxel in combination with 5-fluorouracil (5-FU) in…”
Get full text

Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma by FORD, H. E. R, CUNNINGHAM, D, ROSS, P. J, RAO, S, AHERNE, G. W, BENEPAL, T. S, PRICE, T, MASSEY, A, VERNILLET, L, GRUIA, G

“…To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of irinotecan and raltitrexed given as sequential short infusions every 3…”
Get full text

Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer by Campone, M., Fumoleau, P., Delecroix, V., Deporte-Fety, R., Perrocheau, G., Vernillet, L., Borg-Olivier, O., Louboutin, J. P., Bissery, M.-C., Riva, A., Azli, N.

“…Background and purpose: Anthracycline-containing regimens are widely used in advanced breast cancer. However, there is a need for new, non-anthracycline…”
Get full text

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer by VASEY, P. A, ROCHE, H, BISSET, D, TERRET, C, VERNILLET, L, RIVA, A, RAMAZEILLES, C, AZLI, N, KAYE, S. B, TWELVES, C. J

“…This phase I was study conducted to establish the maximum tolerated dose, dose-limiting toxicity, and recommended dose of docetaxel in combination with…”
Get full text

355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449 by Rudin, C.M, Von Hoff, D.D, LoRusso, P.M, Vernillet, L, Yauch, R, Darbonne, W.C, Mackey, H, de Sauvage, F.J, Low, J.A, Reddy, J.C

Get full text

A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere®) in human plasma using a column switching technique by Rouini, M.R, Lotfolahi, A, Stewart, D.J, Molepo, J.M, Shirazi, F.H, Vergniol, J.C, Tomiak, E, Delorme, F, Vernillet, L, Giguere, M, Goel, R

“…A rapid, simple and sensitive isocratic high performance liquid chromatography (HPLC) method was developed to measure the concentration of docetaxel in plasma…”
Get full text

Noninterchangeability of specific radioimmunoassay and monoclonal antibody fluorescent polarization immunoassay in cyclosporine measurements by Pape, D, Vernillet, L, Bellissant, E, Bentue-Ferrer, D, Allain, H

“…This study compares cyclosporine (CsA) concentrations in whole blood from patients receiving bone marrow (n = 10), renal (n = 48), heart (n = 50) or liver (n =…”
Get more information

Blood cyclosporin A and metabolite kinetic profiles after administration of Sandimmune soft gelatine capsules and Neoral in transplant recipients by Vernillet, L, Kovarik, J M, Freiburghaus, R, Schaub, P, Mueller, E A, Niederberger, W, Zehender, H

Get more information

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment by Mayer, Michael D, Khosravan, Reza, Vernillet, Laurent, Wu, Jing-Tao, Joseph-Ridge, Nancy, Mulford, Darcy J

“…To assess the safety, pharmacokinetics, and pharmacodynamics of febuxostat in subjects with normal renal function or renal impairment, febuxostat (80 mg/d) was…”
Get full text

Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans by Santos, A, Zanetta, S, Cresteil, T, Deroussent, A, Pein, F, Raymond, E, Vernillet, L, Risse, M L, Boige, V, Gouyette, A, Vassal, G

“…7-Ethyl-10[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11), a DNA topoisomerase I inhibitor, undergoes several metabolic pathways to generate…”
Get full text

Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit by Holt, D W, Johnston, A, Marsden, J T, Vernillet, L, Keown, P A, Rosano, T G, Shaw, L M, Rosenthaler, J

“…The performance of a radioimmunoassay kit containing monoclonal specific and nonspecific antibodies to cyclosporine (Sandimmun-Kit; Sandoz Ltd., Basle,…”
Get more information

The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase by Khosravan, Reza, Grabowski, Brian A., Mayer, Michael D., Wu, Jing-Tao, Joseph-Ridge, Nancy, Vernillet, Laurent

“…To assess the effect of hepatic impairment on the pharmacokinetics, pharmacodynamics, and safety of febuxostat at steady state, multiple once‐daily 80‐mg oral…”
Get full text

Influence of different parameters for the monitoring of cyclosporine by Humbert, H, Vernillet, L, Cabiac, M D, Barradas, J, Billaud, E

Get more information

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction by Raymond, Eric, Boige, Valérie, Faivre, Sandrine, Sanderink, Ger-Jan, Rixe, Olivier, Vernillet, Laurent, Jacques, Christian, Gatineau, Michel, Ducreux, Michel, Armand, Jean-Pierre

“…To determine the recommended dose (RD) and the pharmacokinetic profile of irinotecan and its metabolites in cancer patients with hyperbilirubinemia. Patients…”
Get full text

Metabolism of irinotecan (CPT-11) by human hepatic microsomes : Participation of cytochrome P-450 3A and drug interactions by HAAZ, M.-C, RIVORY, L, RICHE, C, VERNILLET, L, ROBERT, J

“…Irinotecan (CPT-11) is a water-soluble analogue of camptothecin showing activity in colon cancer. Recently, we identified a major metabolite of CPT-11 in…”
Get full text